PART I Overview We are a leading, global biotechnology company with a clear and compelling mission to develop and deliver transformative medicines for people living withrarediseases. With extraordinary patient focus, we strive toredefineexpectationsinraredisease. Our two marketed therapies are Galafold , the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda , a novel two-component treatment for adults living with late-onset Po...
Q2 FY2026 — expected 2026-07-19
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-20 | 2025-12-31 | 0001178879-26-000005 | EDGAR | 102K words |
| 2025-02-19 | 2024-12-31 | 0001178879-25-000003 | EDGAR | — |
| 2024-02-28 | 2023-12-31 | 0001178879-24-000003 | EDGAR | — |
| 2023-03-01 | 2022-12-31 | 0001178879-23-000004 | EDGAR | — |
| 2022-02-24 | 2021-12-31 | 0001178879-22-000006 | EDGAR | — |
| 2021-03-01 | 2020-12-31 | 0001178879-21-000004 | EDGAR | — |
| 2020-03-02 | 2019-12-31 | 0001178879-20-000015 | EDGAR | — |
| 2019-02-28 | 2018-12-31 | 0001178879-19-000024 | EDGAR | — |
| 2018-03-01 | 2017-12-31 | 0001047469-18-001199 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-04 | 2025-09-30 | 0001178879-25-000015 | EDGAR | 16K words |
| 2025-07-31 | 2025-06-30 | 0001178879-25-000011 | EDGAR | — |
| 2025-05-01 | 2025-03-31 | 0001178879-25-000006 | EDGAR | — |
| 2024-11-06 | 2024-09-30 | 0001178879-24-000013 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001178879-24-000009 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001178879-24-000006 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0001178879-23-000016 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0001178879-23-000013 | EDGAR | — |
| 2023-05-10 | 2023-03-31 | 0001178879-23-000009 | EDGAR | — |
| 2022-11-07 | 2022-09-30 | 0001178879-22-000018 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001178879-22-000014 | EDGAR | — |
| 2022-05-10 | 2022-03-31 | 0001178879-22-000011 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-03 | 0001140361-26-007544 | EDGAR | 2K words |
| 2026-02-20 | 0001104659-26-018127 | EDGAR | — |
| 2026-01-26 | 0001140361-26-002299 | EDGAR | — |
| 2025-12-19 | 0001140361-25-046134 | EDGAR | — |
| 2025-11-04 | 0001104659-25-105927 | EDGAR | — |
| 2025-07-31 | 0001104659-25-072447 | EDGAR | — |
| 2025-06-05 | 0001104659-25-056821 | EDGAR | — |
| 2025-05-01 | 0001104659-25-043008 | EDGAR | — |
| 2025-05-01 | 0001104659-25-042841 | EDGAR | — |
| 2025-02-21 | 0001104659-25-016127 | EDGAR | — |
221 total filings indexed. 190 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001178879 |
| Ticker | FOLD |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report